"10.1371_journal.pone.0100951","plos one","2014-07-03T00:00:00Z","Daniel J Hogan; Thomas M Vincent; Sarah Fish; Eric G Marcusson; Balkrishen Bhat; B Nelson Chau; Dimitrios G Zisoulis","Regulus Therapeutics, San Diego, California, United States of America","Conceived and designed the experiments: DGZ DJH EGM BNC. Performed the experiments: DJH DGZ TMV SF. Analyzed the data: DJH DGZ TMV SF. Contributed reagents/materials/analysis tools: BB. Wrote the paper: DGZ DJH EGM BNC.","Regulus Therapeutics Inc. has approved or pending patents involving miRNA technology. More specifically, Regulus holds exclusive rights to patents covering miR-122 anti-miRs and their application in inhibiting HCV replication and miR-21 anti-miRs and their use as cancer and fibrosis therapeutics (U.S. Patents No. 7,232,806, No. 7,307,067, No. 7,582,744 and No. 7,683,036). This does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials.","2014","07","Daniel J Hogan","DJH",7,TRUE,4,4,4,4,TRUE,TRUE,FALSE,0,NA,FALSE
